INOVIQ Limited (ASX:IIQ), a biotechnology company developing exosome-based diagnostics and therapeutics, has announced that Chief Executive Officer Dr Leearne Hinch will step down from her role on 27 October 2026, following a mutual agreement between the Board and Dr Hinch on a planned leadership transition.
Key Points
- CEO Dr Leearne Hinch will step down from her role on 27 October 2026 by mutual agreement with the Board.
- Chairman Peter Gunzburg will assume the role of Executive Chair on an interim basis, receiving no additional remuneration.
- The company has commenced an executive search for a new permanent CEO.
- INOVIQ will update the market on its future plans at the Annual General Meeting on 25 November 2026.
CEO Departure and Interim Leadership Arrangement
INOVIQ disclosed on 23 October 2026 that Dr Leearne Hinch and the Board have mutually agreed she will step down as Chief Executive Officer on 27 October 2026. Chairman Peter Gunzburg will take on the role of Executive Chair on an interim basis while the company conducts a search for a new CEO. The filing states that Mr Gunzburg will receive no additional remuneration in connection with the interim executive appointment. The company said it will advise the market of a new CEO appointment in due course.
Chairman's Statement on Dr Hinch's Tenure
In a statement included in the filing, Chairman Peter Gunzburg noted that Dr Hinch had served INOVIQ for approximately 10 years and described her as having made a significant contribution to the company's development. Mr Gunzburg said the business had evolved from a single asset early-stage technology into a company with two products in market, two products in later-stage development, and one in early development. He expressed confidence in the foundations established for INOVIQ's next phase and extended thanks to Dr Hinch for her leadership, commitment, and contributions.
Annual General Meeting to Address Company Plans
According to the filing, INOVIQ has completed a recent review and will update the market on its plans for the future at the Annual General Meeting, scheduled for 25 November 2026. Dr Hinch, in a statement included in the filing, said it had been a privilege to lead INOVIQ through its transformation into an exosome diagnostics and therapeutics company. She expressed gratitude to her executive team and colleagues and said she was proud of what had been achieved in advancing the business towards development and commercialisation milestones.



Please wait processing your request...